Is a weekly intramuscular injection of 100 mg testosterone (e.g., enanthate or cypionate) appropriate for an adult male with documented low testosterone?

100 mg Weekly Testosterone is an Appropriate Starting Dose for Most Men with Documented Hypogonadism

Yes, 100 mg of intramuscular testosterone (enanthate or cypionate) once weekly is an appropriate and often preferable dosing regimen for men with documented low testosterone. This dose falls within guideline-recommended ranges and may offer advantages over traditional every-two-week dosing.

Guideline-Supported Dosing

The Endocrine Society guidelines explicitly recommend 75-100 mg of testosterone enanthate or cypionate administered intramuscularly weekly, or 150-200 mg every 2 weeks as appropriate regimens 1. The FDA label for testosterone cypionate confirms that 50 to 400 mg should be administered every two to four weeks for replacement therapy 2.

Why Weekly Dosing May Be Better

The goal is to achieve mid-normal testosterone levels (approximately 450-600 ng/dL) with stable concentrations throughout the dosing interval 1. When measuring testosterone on injectable therapy, levels should be checked midway between injections—if testosterone is >700 ng/dL or <350 ng/dL at that midpoint, the dose or frequency should be adjusted 1, 3.

Advantages of 100 mg Weekly Over 200 mg Biweekly:

• Reduced peak-to-trough fluctuations: Weekly dosing creates more stable testosterone levels, minimizing the supraphysiological peaks and subtherapeutic troughs seen with larger, less frequent injections 4, 5

• Lower risk of erythrocytosis: Recent evidence shows men receiving 100 mg weekly were significantly less likely to develop hematocrit >54% compared to 200 mg every 2 weeks (1% vs 8%, p=0.023) 4

• Fewer mood and libido fluctuations: Guidelines specifically note that injectable testosterone esters can cause "fluctuations in mood or libido" as a formulation-specific adverse effect 1—weekly dosing mitigates this

• More interpretable lab monitoring: Stable levels make it easier to assess whether the patient is in the therapeutic range 5

Critical Monitoring Requirements

Regardless of dosing frequency, all men on testosterone therapy require structured monitoring 1, 6, 3:

Initial Assessment (3 months):

• Testosterone level (midway between injections for weekly dosing)
• Hematocrit (stop if >54%, evaluate for hypoxia/sleep apnea, restart at reduced dose)
• PSA and digital rectal exam (for men 40+ with baseline PSA >0.6 ng/mL)
• Symptom response assessment

Annual Monitoring:

• Testosterone level
• Hematocrit
• PSA/DRE (age-appropriate)
• Bone density after 1-2 years if osteoporosis present

Red Flags Requiring Urological Consultation:

• PSA increase >1.4 ng/mL within 12 months
• Confirmed PSA >4.0 ng/mL
• Prostatic abnormality on exam
• Severe urinary symptoms (AUA/IPSS >19)

Important Caveats

Testosterone therapy should only be initiated in men with:

• Documented low testosterone on two separate morning measurements using a reliable assay 1
• Clinically significant symptoms of androgen deficiency (sexual dysfunction, fatigue, reduced muscle mass, etc.)
• No absolute contraindications: prostate or breast cancer, hematocrit >50%, untreated sleep apnea, severe heart failure, palpable prostate nodule 1

Do not treat all older men with low testosterone—the Endocrine Society explicitly recommends against general screening and treatment of asymptomatic older men 1. Treatment should be individualized for symptomatic men after explicit discussion of uncertain long-term risks and benefits 1.

Dose Adjustment Strategy

If symptoms persist or labs are suboptimal on 100 mg weekly:

• First check timing: Measure testosterone midway between injections (3-4 days after injection for weekly dosing)
• If mid-interval testosterone <350 ng/dL: Increase dose incrementally
• If mid-interval testosterone >700 ng/dL: Decrease dose
• If symptoms cycle despite appropriate levels: Consider more frequent injections (twice weekly at 50 mg) rather than dose escalation 5

Historical data from 1980 showed that 100 mg weekly produced the highest average testosterone concentrations and best LH/FSH suppression compared to less frequent higher doses 7, supporting this as an effective regimen.

Bottom Line

100 mg intramuscular testosterone weekly is guideline-concordant, effective, and may offer safety advantages over traditional biweekly dosing 1, 4. It should be initiated only after proper diagnosis with two low morning testosterone measurements and compatible symptoms, with mandatory monitoring of hematocrit, PSA, and testosterone levels at 3 months and annually thereafter 1, 6, 3.